How Ossium Health Is Building an Off-the-Shelf Bone Marrow Transplant Model

Key Takeaways

• Ossium uses deceased donor marrow, creating off‑the‑shelf product
• PRESERVE I trial has completed ~25 transplants to date
• Banked marrow yields higher cell doses, supporting larger patients
• Global shipping validated for 10 days, expanding access worldwide
• Infrastructure spans US organ recovery networks, enabling several donors daily

Pulse Analysis

Bone‑marrow transplantation remains a lifesaving yet logistically complex therapy, relying on live donors who must match the patient’s HLA profile and be available at the exact moment of need. This dependence creates months‑long delays, dose limitations for larger patients, and geographic barriers that exclude up to 70% of candidates without a familial match. Ossium Health’s strategy flips the model by harvesting marrow from deceased organ donors, cryopreserving it, and maintaining a ready‑to‑use inventory. The approach not only sidesteps donor‑search timelines but also captures substantially more stem cells per donor, ensuring adequate dosing regardless of patient size.

The company’s first‑in‑human PRESERVE I study, now enrolling patients with hematologic malignancies, has already performed roughly 25 transplants. Early data presented at the 2026 Tandem Meetings indicate robust engraftment and manageable safety profiles, validating the cryopreservation process. A key operational advantage is the product’s 10‑day validated shipping window, allowing hospitals worldwide to receive high‑dose marrow on demand. By partnering with the World Marrow Donor Association, Ossium aims to list its units in the global registry, further streamlining cross‑border access and reducing reliance on local donor pools.

Beyond immediate transplant applications, Ossium envisions its marrow bank as a versatile cell‑therapy platform. The repository contains diverse hematopoietic progenitors, lymphocytes, and other immune cells that can be isolated, engineered, and redeployed as allogeneic CAR‑T or NK‑cell products. This allogeneic, off‑the‑shelf paradigm aligns with the industry’s shift toward scalable, off‑the‑shelf immunotherapies that can serve tens of thousands of patients annually. If successful, Ossium’s model could catalyze a new wave of cell‑based treatments, attract strategic partnerships, and reshape the economics of hematologic care.